Abstract 6101
Background
Vascular endothelial growth factor (VEGF) is a glycoprotein growth factor specific for vascular endothelial cells, responsible for angiogenesis. So far, 44 SNPs with clinical relevance have been detected (ClinVar NCBI database) and the majority of those are associated with cancers of colon and others solid tumors. The aim of this study was to assess the distribution of + 405C>G VEGF gene polymorphism in patients diagnosed with glioblastoma and to test association with the overall survival.
Methods
Tissue paraffin-embedded samples were subjected to molecular analyses and VEGF polymorphism detection retrieved from 66 patients diagnosed for glioblastoma. VEGF genotypes at position The most frequent allele (SNP variant) was G (72.58%) (Table). No statistically significant differences were observed in a pairwise genotype groups comparison for overall survival (OS). Between-group variance is negative (-3,840), indicating no differences in mean OS among genotypes. ANOVA also did not show any statistically significant variance among groups (F = 0.124; p = 0.879).Table: 390P Descriptive statistics for overall survival in three genotypes of VEGF gene N – number of patients; OS – overall survival in months; SD – standard deviation; SE – standard error; CI – confidence interval; min – minimum in months; max – maximum in monthResults
Genotype N Mean OS SD SE CI (95%) lower upper CC 9 10.56 8.918 2.973 3.70 17.41 CG 32 11.00 9.449 1.670 7.59 14.41 GG 21 12.10 8.420 1.837 8.26 15.93 Total 62 11.31 8.910 1.132 9.04 13.57
Conclusions
Even though no significant difference in overall survival in GBM patients regarding the examined polymorphism of VEGF gene was found, it was also shown that genotype GG has one month longer overall survival in the examined patients group. It is probable that random selection of patients regardless of applied treatment, or without treatment, and ECOG 1-4 requires larger number of patients to be included in order to provide final proof whether this polymorphism has any effect on overall survival.
Clinical trial identification
Legal entity responsible for the study
Milos Lucic.
Funding
Provincial Secretariat for High Education and Science of Vojvodina Province.
Editorial Acknowledgement
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2595 - Real-Life Utilization of Genomic testing for invasive Breast Cancer patients in Italy and France reduces Chemotherapy Recommendations
Presenter: Sandro Barni
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2343 - Benefit of adjuvant chemotherapy in hormone receptor-positive, HER2-negative, invasive lobular carcinoma of the breast
Presenter: Alexandre De Nonneville
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2990 - Baseline lymphocyte counts predict distant recurrence in early breast cancer
Presenter: Gun Min Kim
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4532 - A propensity score analysis exploring the impact of the addition of adjuvant chemotherapy (aCT) to hormone therapy (aHT) in a multi-center series of resected luminal early stage pure Invasive Lobular Breast Carcinoma (ILC).
Presenter: Luisa Carbognin
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2344 - Benefit of Adjuvant Systemic Therapies in HR+ HER2- pT1ab Node-Negative Breast Carcinomas
Presenter: Alexandre De Nonneville
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3525 - Anti-proliferative effect of oral metronomic vinorelbine in PAM50 Luminal/HER2-negative early breast cancer (SOLTI-1501 VENTANA): an open-label, randomized, three-arm, multicenter, window-of-opportunity study
Presenter: Aleix Prat
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3908 - Clinicopathologic significance of androgen receptor expression and discordant receptor status during progression in breast cancer
Presenter: Chan Heun Park
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4075 - The outcomes of early breast cancers utilizing the Oncotype Dx Recurrence score (RS) instead of Clinico-pathological (CP) factors for prognostic risk assessment: A Single Institution Experience
Presenter: Adhar Alsayed
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
738 - Circulating tumor cells as a prognostic marker in non metastatic breast cancer patients.
Presenter: Summar Elmorshidy
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3151 - Molecular subtyping of breast cancer by dedicated breast PET
Presenter: Satoshi Sueoka
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract